Aragon Pharmaceuticals is focused on the development of second-generation anti-hormonal agents for hormone-driven cancers, including its lead compound ARN-509 for prostate cancer and ARN-810 for breast cancer
Aragon Pharmaceuticals is focused on the development of second-generation anti-hormonal agents for hormone-driven cancers, including its lead compound ARN-509 for prostate cancer and ARN-810 for breast cancer.